Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Complex Partial Seizure

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    59 result(s) found for: Complex Partial Seizure. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2009-016996-31 Sponsor Protocol Number: P09-004 Start Date*: 2010-06-28
    Sponsor Name:Upsher-Smith Laboratories, Inc.
    Full Title: A Randomized, Multicenter, Double-Blind, Placebo–Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients with Refractory Partial-O...
    Medical condition: Refractory partial-onset seizures with or without secondary generalization
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10056209 Partial seizures with secondary generalisation PT
    14.0 10029205 - Nervous system disorders 10034090 Partial seizures, complex LLT
    14.0 10029205 - Nervous system disorders 10040703 Simple partial seizures PT
    14.0 10029205 - Nervous system disorders 10048674 Partial seizures with secondary generalization LLT
    14.0 10029205 - Nervous system disorders 10010145 Complex partial seizures PT
    14.0 10029205 - Nervous system disorders 10034091 Partial seizures, simple LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) GR (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005440-25 Sponsor Protocol Number: SP904 Start Date*: 2009-02-16
    Sponsor Name:UCB BIOSCIENCES, Inc.
    Full Title: A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-onset Seizures
    Medical condition: Partial-onset seizures (with and without secondary generalization)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10010145 Complex partial seizures PT
    16.1 10029205 - Nervous system disorders 10040703 Simple partial seizures PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) ES (Completed) AT (Completed) DK (Completed) PT (Not Authorised) IT (Completed) FR (Completed) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-017904-95 Sponsor Protocol Number: P09-005 Start Date*: 2010-06-28
    Sponsor Name:Upsher-Smith Laboratories, Inc.
    Full Title: Open-Label Extension Study to Evaluate the Safety of USL255 as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures who had Participated in P09-004, a Randomized, Multicenter, Doub...
    Medical condition: Refractory partial-onset seizures with or without secondary generalization
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10056209 Partial seizures with secondary generalisation PT
    14.0 10029205 - Nervous system disorders 10034090 Partial seizures, complex LLT
    14.0 10029205 - Nervous system disorders 10040703 Simple partial seizures PT
    14.0 10029205 - Nervous system disorders 10048674 Partial seizures with secondary generalization LLT
    14.0 10029205 - Nervous system disorders 10010145 Complex partial seizures PT
    14.0 10029205 - Nervous system disorders 10034091 Partial seizures, simple LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) GR (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005439-27 Sponsor Protocol Number: SP902 Start Date*: 2009-02-16
    Sponsor Name:UCB BIOSCIENCES, Inc.
    Full Title: A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400mg/day Monotherapy in Subjects with Partial-onset Seizures
    Medical condition: Partial-onset seizures (with or without secondary generalization)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10040703 Simple partial seizures PT
    14.0 10029205 - Nervous system disorders 10010145 Complex partial seizures PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) ES (Completed) AT (Completed) DK (Completed) PT (Not Authorised) IT (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001982-33 Sponsor Protocol Number: E2090-E044-401 Start Date*: 2005-09-05
    Sponsor Name:Eisai Limited
    Full Title: An open label study of Zonegran (zonisamide) in patients with partial onset seizures.
    Medical condition: Indicated as adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10061334 pt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) SE (Completed) DK (Completed) FI (Completed) DE (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003941-17 Sponsor Protocol Number: 333369EPY3002 Start Date*: 2007-02-22
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A randomized,double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety and tolerability of RWJ333369 as adjunctive therapy in subjects with partial onset...
    Medical condition: Partial Onset Epilepsy Seizures
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004334-26 Sponsor Protocol Number: N01222 Start Date*: 2015-02-10
    Sponsor Name:UCB Japan Co. Ltd
    Full Title: A Multicenter, Open, Long-term Follow-up Study to Evaluate the Safety and Efficacy of L059 (Levetiracetam) at Individual Optimal Dose Ranging From 500 to 3000 mg/Day in Twice Daily Administration i...
    Medical condition: Epilepsies Partial
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002167-16 Sponsor Protocol Number: E2007-G000-311 Start Date*: 2017-01-30
    Sponsor Name:Eisai Limited
    Full Title: An Open-Label, Multicenter Study with an Extension Phase to Evaluate the Safety, Tolerability, and Exposure-Efficacy Relationship of Perampanel Oral Suspension when Administered as an Adjunctive Th...
    Medical condition: Epilepsy : 1) Partial-Onset Seizures (POS) 2) Primary Generalized Tonic-Clonic Seizures (PGTC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10018101 Generalised tonic-clonic seizures HLT
    19.0 10029205 - Nervous system disorders 10061334 Partial seizures PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) ES (Completed) PL (Completed) BE (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-020871-22 Sponsor Protocol Number: AGG-901 Start Date*: 2011-02-02
    Sponsor Name:West-ward Pharmaceutical Corporation
    Full Title: An international, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of phenobarbital as adjunctive therapy in participants (≥ 17 to 70 years ...
    Medical condition: Epilepsy with partial onset seizures (complex or simple with motor symptoms only) whether or not secondarily generalized.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10015037 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016849-25 Sponsor Protocol Number: A0081047 Start Date*: 2010-03-15
    Sponsor Name:Pfizer Inc
    Full Title: A DOUBLE-BLIND, RANDOMIZED, MULTICENTER EFFICACY AND SAFETY STUDY OF PREGABALIN (LYRICA) AS MONOTHERAPY IN PATIENTS WITH PARTIAL SEIZURES
    Medical condition: Partial Seizures
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061334 Partial seizures LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005344-27 Sponsor Protocol Number: YKP3089C040 Start Date*: 2022-02-03
    Sponsor Name:SK Life Science, Inc.
    Full Title: Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-onset (Focal) Seizures
    Medical condition: partial onset (focal) seizures
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10016843 Focal seizures LLT
    21.1 10029205 - Nervous system disorders 10061334 Partial seizures PT
    20.0 10029205 - Nervous system disorders 10039910 Seizures LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) HU (Ongoing) PL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017961-52 Sponsor Protocol Number: CBGG492A2207 Start Date*: 2010-05-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-week, multi-center,randomized, double-blind, placebo-controlled efficacy and safety study examining seizure frequency of BGG492 capsules administration orally three times daily (TID) as adjunc...
    Medical condition: refractory partial-onset seizures
    Disease: Version SOC Term Classification Code Term Level
    12.1 10065336 Partial epilepsy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2006-003839-68 Sponsor Protocol Number: 333369-EPY-3001/3004 Start Date*: 2006-11-09
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects with Partial Onse...
    Medical condition: Partial Onset Epilepsy Seizures
    Disease: Version SOC Term Classification Code Term Level
    8.1 10015037 Epilepsy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Prematurely Ended) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-020730-26 Sponsor Protocol Number: A0081074 Start Date*: 2010-10-08
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A PLACEBO-CONTROLLED, ESCALATING DOSE, MULTIPLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PREGABALIN IN PEDIATRIC PATIENTS WITH PARTIAL ONSET SEIZURES
    Medical condition: PARTIAL ONSET SEIZURES
    Disease: Version SOC Term Classification Code Term Level
    12.1 10034089 Partial seizures NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-004484-37 Sponsor Protocol Number: CTRI476B1301 Start Date*: 2016-04-15
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A Multicentre, Randomized, Double-blind, Placebo Controlled, Parallel-group Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Efficacy, Safety and Tolerability of...
    Medical condition: Partial Onset Seizures
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10039910 Seizures LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000860-90 Sponsor Protocol Number: CRAD001M2304 Start Date*: 2013-02-14
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC)...
    Medical condition: Refractory partial-onset seizures associated with tuberous sclerosis complex (TSC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10045138 Tuberous sclerosis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) NL (Completed) DE (Completed) HU (Completed) GB (Completed) BE (Completed) GR (Completed) DK (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011181-28 Sponsor Protocol Number: SP954 Start Date*: 2009-11-02
    Sponsor Name:Schwartz Biosciences, INC - UCB Group
    Full Title: An open-label, multicenter, multinational study of lacosamide as first add-on anti epileptic drug (AED) treatment in subjects with partial onset seizures. ESTUDIO ABIERTO, MULTICÉNTRICO Y MULTINACI...
    Medical condition: Epilepsy / Epilepsia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015037 Epilepsy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) FI (Completed) IT (Completed) PL (Ongoing) NL (Prematurely Ended) BG (Completed) FR (Completed) GR (Completed) HU (Completed) PT (Prematurely Ended) DE (Completed) CZ (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-002182-36 Sponsor Protocol Number: VRX-RET-E22-302 Start Date*: 2006-04-18
    Sponsor Name:Valeant Research & Development
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP PHASE 3 STUDY TO DETERMINE THE EFFICACY AND SAFETY OF TWO DOSES OF RETIGABINE (900 MG/DAY AND 600 MG/DAY) USED AS ADJUNCT...
    Medical condition: Refractory Epilepsy Patients with Partial-Onset Seizures
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) ES (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006168-31 Sponsor Protocol Number: E2007-G000-305 Start Date*: 2008-08-28
    Sponsor Name:Eisai Ltd
    Full Title: A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial S...
    Medical condition: Epilepsy: refractory partial seizures with or without secondary generalisation
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) NL (Completed) DE (Completed) FR (Completed) SE (Completed) GB (Completed) DK (Completed) FI (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-004023-19 Sponsor Protocol Number: A0081046 Start Date*: 2006-05-25
    Sponsor Name:Pfizer Ltd, Ramsgate Rd, Sandwich, Kent, United Kingdom
    Full Title: A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN (LYRICA) AND LAMOTRIGINE (LAMICTAL) IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES
    Medical condition: Epilepsy; Patients with newly diagnosed partial seizures (with or without secondary generalization)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061334 Partial seizures LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) PT (Completed) ES (Completed) BE (Completed) IE (Completed) CZ (Completed) LT (Completed) DE (Completed) SK (Completed) IT (Completed) HU (Completed) FI (Completed) EE (Completed) BG (Completed) LV (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:40:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA